CANDESARTAN TABLET

Quốc gia: Canada

Ngôn ngữ: Tiếng Anh

Nguồn: Health Canada

Thành phần hoạt chất:

CANDESARTAN CILEXETIL

Sẵn có từ:

PRO DOC LIMITEE

Mã ATC:

C09CA06

INN (Tên quốc tế):

CANDESARTAN

Liều dùng:

32MG

Dạng dược phẩm:

TABLET

Thành phần:

CANDESARTAN CILEXETIL 32MG

Tuyến hành chính:

ORAL

Các đơn vị trong gói:

100

Loại thuốc theo toa:

Prescription

Khu trị liệu:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Tóm tắt sản phẩm:

Active ingredient group (AIG) number: 0135220004; AHFS:

Tình trạng ủy quyền:

APPROVED

Ngày ủy quyền:

2014-04-14

Đặc tính sản phẩm

_ _
_Candesartan _
_Page 1 of 35_
PRODUCT MONOGRAPH
PR
CANDESARTAN
Candesartan Cilexetil Tablets
8 mg, 16 mg and 32 mg
Manufacturer's Standard
Angiotensin II AT
1
Receptor Blocker
Pro Doc Ltée
Date of Revision:
2925, boul. Industriel November 10, 2021
Laval, Quebec
H7L 3W9
Submission Control No.: 257568
_ _
_Candesartan _
_Page 2 of 35_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY
PRODUCT
INFORMATION
.................................................................................
3
INDICATIONS
AND
CLINICAL
USE
.......................................................................................
3
CONTRAINDICATIONS
............................................................................................................
4
WARNINGS
AND
PRECAUTIONS
..........................................................................................
4
ADVERSE
REACTIONS
............................................................................................................
8
DRUG
INTERACTIONS
...........................................................................................................
12
DOSAGE
AND
ADMINISTRATION
.......................................................................................
14
OVERDOSAGE
.........................................................................................................................
17
ACTION
AND
CLINICAL
PHARMACOLOGY
.....................................................................
17
STORAGE
AND
STABILITY...................................................................................................
19
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING ...................................................... 19
PART II: SCIENTIFIC INFORMATION
................................................................................
21
PHARMACEUTICAL
INFORMATION
..................................................................................
21
CLINICAL
TRIALS
...........................